Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2016 · 10-Q
Revenue—
Net Income-$2.22M-$2.22MN/M vs Q3 2015 EPS Diluted-$0.02-$0.02N/M vs Q3 2015 Operating Income-$1,310,748— Operating Cash Flowderived-$775,642N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Sep 30, 2016 · filed Nov 14, 2016 · 45 d after period end